Key Stats for Eli Lilly Stock
- Price change for Eli Lilly stock: 3%
- $LLY Share Price as of May. 27: $1,087
- 52-Week High: $1,134
- $LLY Stock Price Target: $1,215
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Eli Lilly (LLY) stock got a lift on Tuesday after Bank of America raised its price target from $1,133 to $1,251, and kept a Buy rating.
- Analyst Jason Gerberry pointed to the company’s dominant position in the GLP-1 market and a pipeline of new obesity drugs that could drive growth well into the next decade.
- The upgrade follows a BofA physician survey that found doctors expect to increase their use of GLP-1 medications over time.
- Gerberry now expects U.S. GLP-1 market sales to roughly double by 2033 — from around $35 billion this year to $79 billion — with Eli Lilly positioned to capture a large share of that growth through new product launches.
Two recent milestones are central to that thesis.
- In April, the FDA approved Foundayo, Lilly’s oral GLP-1 pill for obesity. It’s the first incretin medicine ever launched with obesity as its primary indication.
- Then last week, retatrutide — Lilly’s next-generation triple agonist — cleared a major Phase III obesity trial, posting weight-loss results that exceeded those of standard GLP-1 drugs.
See analysts’ growth forecasts and price targets for Eli Lilly stock (It’s free) >>>
What the Market Is Telling Us About Eli Lilly Stock
Eli Lilly stock is still down about 3% year to date. That underperformance relative to the broader drug sector is part of what makes the case compelling to BofA. The analyst noted that Eli Lilly is trading below where its growth profile deserves.
The Q1 2026 earnings report underscored just how fast the business is moving.
- Revenue grew 56% year-over-year.
- Combined global sales of Mounjaro and Zepbound hit $12.8 billion in a single quarter.
- The company raised its full-year revenue guidance to a range of $82 to $85 billion — implying 28% growth at the midpoint.
Foundayo’s early launch data is also encouraging. More than 20,000 patients have started the drug. Roughly 80% of Foundayo prescriptions go to patients who are new to the GLP-1 class, suggesting the pill is expanding the market rather than just cannibalizing existing injectable users.
BofA also flagged that Lilly’s obesity pipeline — including retatrutide and eloralintide — could extend revenue growth beyond 2036, when Mounjaro’s patent protection begins to expire.
With Medicare GLP-1 access set to begin in July and a full consumer advertising push for Foundayo planned in Q3, Eli Lilly stock has several near-term catalysts still ahead.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Eli Lilly Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
